Literature DB >> 35058288

The Pellino1-PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function.

Jihyun Park1, Si-Yeon Lee2, Yoon Jeon2,3, Kyung-Mo Kim2, Jin-Kwan Lee4, Jiwon Ko5, Eun-Ji Park2, Joon-Sup Yoon2, Baeki E Kang6, Dongryeol Ryu6, Ho Lee3, Su-Jin Shin7, Heounjeong Go5, Chang-Woo Lee1,2,8.   

Abstract

CD8+ T cells play an important role in the elimination of tumors. However, the underlying mechanisms involved in eliciting and maintaining effector responses in CD8+ T cells remain to be elucidated. Pellino1 (Peli1) is a receptor signal-responsive ubiquitin E3 ligase, which acts as a critical mediator for innate immunity. Here, we found that the risk of developing tumors was dependent on Peli1 expression. Peli1 was upregulated in CD8+ T cells among tumor-infiltrating lymphocytes (TIL). In contrast, a deficit of Peli1 enhanced the maintenance and effector function of CD8+ TILs. The development of Peli1-deficient CD8+ TILs prevented T-cell exhaustion and retained the hyperactivated states of T cells to eliminate tumors. We also found that Peli1 directly interacted with protein kinase C-theta (PKCθ), a central kinase in T-cell receptor downstream signal transduction, but whose role in tumor immunology remains unknown. Peli1 inhibited the PKCθ pathway by lysine 48-mediated ubiquitination degradation in CD8+ TILs. In summary, the Peli1-PKCθ signaling axis is a common inhibitory mechanism that prevents antitumor CD8+ T-cell function, and thus targeting Peli1 may be a useful therapeutic strategy for improving cytotoxic T-cell activity. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35058288     DOI: 10.1158/2326-6066.CIR-21-0419

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  2 in total

1.  The E3 Ubiquitin Ligase Peli1 Deficiency Promotes Atherosclerosis Progression.

Authors:  Fabienne Burger; Daniela Baptista; Aline Roth; Karim J Brandt; Kapka Miteva
Journal:  Cells       Date:  2022-06-23       Impact factor: 7.666

Review 2.  T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy.

Authors:  Zhanyan Gao; Yang Feng; Jinhua Xu; Jun Liang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.